ImmuPharma PLC

LSE:IMM (UK)  
£ 0.02 (0%) Apr 26
At Loss
P/B:
4.28
Market Cap:
£ 8.91M ($ 11.26M)
Enterprise V:
£ 8.70M ($ 11.00M)
Volume:
604.70K
Avg Vol (2M):
3.51M
Also Trade In:
Volume:
604.70K
At Loss
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for ImmuPharma PLC ( ) from 2003 to Apr 28 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. ImmuPharma PLC stock (LSE:IMM) PE ratio as of Apr 28 2024 is 0. More Details

ImmuPharma PLC (LSE:IMM) PE Ratio (TTM) Chart

To

ImmuPharma PLC (LSE:IMM) PE Ratio (TTM) Historical Data

Total 1240
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
ImmuPharma PLC PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-04-29 At Loss 2024-02-22 At Loss
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss
2024-04-05 At Loss 2024-01-31 At Loss
2024-04-04 At Loss 2024-01-30 At Loss
2024-04-03 At Loss 2024-01-29 At Loss
2024-04-02 At Loss 2024-01-26 At Loss
2024-03-28 At Loss 2024-01-25 At Loss
2024-03-27 At Loss 2024-01-24 At Loss
2024-03-26 At Loss 2024-01-23 At Loss
2024-03-25 At Loss 2024-01-22 At Loss
2024-03-22 At Loss 2024-01-19 At Loss
2024-03-21 At Loss 2024-01-18 At Loss
2024-03-20 At Loss 2024-01-17 At Loss
2024-03-19 At Loss 2024-01-16 At Loss
2024-03-18 At Loss 2024-01-15 At Loss
2024-03-15 At Loss 2024-01-12 At Loss
2024-03-14 At Loss 2024-01-11 At Loss
2024-03-13 At Loss 2024-01-10 At Loss
2024-03-12 At Loss 2024-01-09 At Loss
2024-03-11 At Loss 2024-01-08 At Loss
2024-03-08 At Loss 2024-01-05 At Loss
2024-03-07 At Loss 2024-01-04 At Loss
2024-03-06 At Loss 2024-01-03 At Loss
2024-03-05 At Loss 2024-01-02 At Loss
2024-03-04 At Loss 2023-12-29 At Loss
2024-03-01 At Loss 2023-12-28 At Loss
2024-02-29 At Loss 2023-12-27 At Loss
2024-02-28 At Loss 2023-12-22 At Loss
2024-02-27 At Loss 2023-12-21 At Loss
2024-02-26 At Loss 2023-12-20 At Loss
2024-02-23 At Loss 2023-12-19 At Loss

ImmuPharma PLC (LSE:IMM) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus and a life-threatening autoimmune disease.